GlassScriptPhysician profile
Sasha Bravo
NPI 1841883030
$790.90
in general payments reported to CMS, 2019-2025
10 companies · $34.64 in 2025
The $34.64 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $68.24 · 2023: $438 · 2024: $125 · 2025: $34.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $597.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $164.06 | 2023 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $155.00 | 2021-2023 | |
| Idorsia Pharmaceuticals US INC | $142.93 | 2023-2024 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $98.43 | 2022-2023 | |
| Lundbeck LLC | $97.54 | 2023-2025 | Rexulti |
| Neos Therapeutics, LP | $49.88 | 2021-2023 | Adzenys Xr-Odt |
| Otsuka America Pharmaceutical, INC. | $29.85 | 2023 | Rexulti |
| Tris Pharma INC | $22.33 | 2023 | Dyanavel Xr |
| Corium, LLC | $15.56 | 2023 | Azstarys |
| Vanda Pharmaceuticals INC. | $15.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sasha Bravo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.